Sanofi- and Gilead Sciences-backed Nurix Therapeutics is following suit with rival biotech Kymera in raising a major cash haul for its protein modulation R&D work.
After Kymera's raise, Nurix nabs $120M as it too hones in on clinical work
top of page
bottom of page
Opmerkingen